NCT03354728View on ClinicalTrials.gov

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 11, 2018

Primary Completion Date

December 11, 2026

Study Completion Date

December 11, 2026

Conditions
Cytomegaloviral InfectionHematopoietic Cell Transplant Recipient
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Given IM

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER